Medical/Pharmaceuticals

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research  LAUSANNE, Switzerland, Oct. 3, 2022 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global bioph...

2022-10-03 15:00 1406

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2023

GOTHENBURG, Sweden, Oct.1, 2022 /PRNewswire/ -- Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee for the company's Annual General Meeting 2023 has been appointed. ...

2022-10-01 00:53 2509

Infinitus Products Received the Hong Kong Q-Mark Certificate

GUANGZHOU, China, Sept. 30, 2022 /PRNewswire/ -- The Q-Mark 43rd Anniversary cum Presentation Ceremony has been successfully held at the Hong Kong Convention and Exhibition Centre on2 September 2022. Nine Infinitus Products Have Received the Hong Kong Q-Mark Product Certification.

2022-09-30 19:23 1821

YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.

* Transaction values YS Biopharma at pre-money equity value of $834 million * Certain investors ("Forward Purchase Investors") are expected to invest $30 million in a private placement concurrently with the closing of the business combination transaction pursuant to certain forward purchase ag...

2022-09-30 04:01 2490

First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent

MELBOURNE, Australia, Sept. 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose inNew Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known ...

2022-09-30 02:30 2035

Doxy.me extends telemedicine's reach to 88% of the world's population

Doxy.me adds over 100 languages, live interpreters, and global currencies to overcome barriers to telemedicine around the world. CHARLESTON, S.C., Sept. 30, 2022 /PRNewswire/ -- Doxy.me, the web-based telemedicine platform on a mission to make telemedicine available to all, is expanding its capa...

2022-09-29 22:03 1572

XSENSOR Earns the Frost & Sullivan 2022 Technology Innovation Leadership Award for Intelligent Dynamic Sensing Systems

Delivers innovative pressure measurement solutions to the world's most demanding customers. SAN ANTONIO, Sept. 29, 2022 /PRNewswire/ -- Based on its recent analysis of the sensor technology in the medical devices market,Frost & Sullivan recognizes XSENSOR Technology Corporation with the 2022 Nor...

2022-09-29 21:00 1209

'Generations Connect' Project Brings Young People Together with the Elderly to Boost Emotional Resilience

Engaging tailored e-platform and healthcare students promote the wellbeing of the elderly HONG KONG, Sept. 29, 2022 /PRNewswire/ -- In recent years due to the COVID-19 pandemic, elderly people have had to stay mostly at home. Confined to small living spaces for prolonged periods, many senior cit...

2022-09-29 17:37 2481

Manulife Hong Kong research reveals attitude shift on how Hongkongers live with COVID-19

* Hong Kong residents are trying to regain normalcy in daily lives * Mental and physical health in decline * Majority of respondents concerned about spread of another unknown disease in Hong Kong HONG KONG, Sept. 29, 2022 /PRNewswire/ -- Manulife Hong Kong today announced the results of its h...

2022-09-29 13:13 3051

Green Mountain Biotech and Kamedis Announce First Patent in China for Unique Herb-Based Acne and Skin Relief Solution

Clinically-tested solution, based on a proprietary blend of six herbs used in Traditional Chinese Medicine, helps relieve symptoms of acne and other skin inflammation conditions. TEL AVIV, Israel, Sept. 29, 2022 /PRNewswire/ -- Green Mountain Biotech (GMB), the ...

2022-09-29 09:00 1732

Green Mountain Biotech and Kamedis Announce First Patent in China for Unique Herb-Based Acne and Skin Relief Solution

Clinically-tested solution, based on a proprietary blend of six herbs used in Traditional Chinese Medicine, helps relieve symptoms of acne and other skin inflammation conditions. TEL AVIV, Israel, Sept. 29, 2022 /PRNewswire/ -- Green Mountain Biotech (GMB), the ...

2022-09-29 09:00 1310

CLIMATE CHANGE AND HEALTH INEQUITY A DEADLY MIX FOR THE MOST VULNERABLE: WORLD HEART FEDERATION

GENEVA, Sept. 29, 2022 /PRNewswire/ -- On World Heart Day, the World Heart Federation (WHF) is calling for urgent action on climate change and health inequity, saying millions more lives are now at risk from cardiovascular disease, which is still the world's biggest killer. Climate change and ai...

2022-09-29 06:01 1754

ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world

* ASTRUM-005 is the first study to demonstrate that PD-1 inhibitors plus chemotherapy can improve survival for patients with ES-SCLC. * In ASTRUM-005, serplulimab combined with chemotherapy achieved by far the longest OS in first-line immunotherapy for ES-SCLC. Compared with chemotherapy, the...

2022-09-28 21:00 1837

ICHNOS SCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN STUDY FOR ISB 1442

First patient dosed with novel biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in oncology, today anno...

2022-09-28 20:30 1195

ABILITY DIABETES GLOBAL - A Landmark RCT in the field of PCI for patients with DM, completes Enrolment

TAMPA, Fla., Sept. 28, 2022 /PRNewswire/ -- ABILITY DIABETES-GLOBAL  (ADG), is the World's largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing head-to-head the Sirolimus eluting ste...

2022-09-28 20:29 1695

Advanced Instruments Introduces Solentim VIPS™ PRO, A High Efficiency Single Cell Seeder to Optimize Cell Line Development Workflows

VIPS PRO delivers powerful and efficient seeding technology and definitive proof of monoclonality for workflow productivity and confidence. NORWOOD, Mass., Sept. 28, 2022 /PRNewswire/ -- Advanced Instruments today announced the launch ofSolentim VIPS PRO, a high efficiency single cell seeder, at...

2022-09-28 20:05 1680

The IND application of Biosyngen BRG01 Therapy was accepted by CDE

GUANGZHOU, China, Sept. 28, 2022 /PRNewswire/ -- The IND application of Biosyngen BRG01 Therapy has been accepted for review by the Center for Drug Evaluation,China (CXSL2200487)( https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d

2022-09-28 18:05 3333

Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

SINGAPORE, Sept. 28, 2022 /PRNewswire/ -- On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a base to develop the company's immunotherapy assets to address unmet needs in cancer treatment. Located in Solaris @ Tai Seng, this 1,300 square metres faci...

2022-09-28 17:34 4279

New GHA Certification Helps Medical Tourism Facilitators Build Patient Trust

WEST PALM BEACH, Fla., Sept. 28, 2022 /PRNewswire/ -- Global Healthcare Accreditation (GHA) announces the launch of a new certification program for medical travel facilitators to assist in building patient trust.  GHA's Medical Travel Facilitator Certification focuses on validating the capacity ...

2022-09-28 17:00 1841

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology

CAMBRIDGE, England and COPENHAGEN, Denmark, Sept. 28, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S ("Contera") are pleased to announce a strategic drug discovery collaboration on an undisclosed target. Under the terms of the...

2022-09-28 16:00 1435
1 ... 121122123124125126127 ... 383